• Sulfo-Cy3 Azide: Identity and Evidence Scope

  2026-10-19

  Sulfo-Cy3 azide (SKU A8127) is a sulfonated fluorescent bioconjugation reagent described for azide–alkyne Click Chemistry fluorescent labeling in aqueous biological contexts. The supplied evidence supports its identity and intended optical scope, but not independent claims about labeling efficiency or biological performance.

• DZNep: Mechanism, Evidence, and Scope

  2026-10-19

  The APExBIO product description identifies 3-Deazaneplanocin A hydrochloride (DZNep, A8182) as an epigenetic research compound associated with EZH2/PRC2, H3K27me3, and S-adenosylhomocysteine hydrolase. It reports findings in AML cell lines and a diet-induced rat model of NAFLD, but provides no identity-matched paper, effect sizes, sample sizes, uncertainty estimates, or independent comparator; the evidence therefore supports a conceptual mechanism overview rather than efficacy or target-selective conclusions.

• Miransertib: Evidence-Limited Product Overview

  2026-10-18

  The available APExBIO product information identifies Miransertib under SKU C8430, but provides no identity-matched research paper, mechanistic description, assay readout, outcome statistics, or comparative evidence. Accordingly, this overview distinguishes catalog-level identification from research evidence and does not assign a molecular target, mechanism, or performance claim that is not documented in the supplied material.

• EPZ015666: Evidence and Scope of the Product Record

  2026-10-17

  The available APExBIO catalog record identifies EPZ015666 as product B4989, but it provides no mechanism, assay readout, structural annotation, or identity-matched research evidence. The record therefore supports only a limited catalog-level description, not conclusions about molecular activity, selectivity, efficacy, or translational relevance.

• 2-Thio-dCTP: Identity, Mechanism, and Evidence

  2026-10-16

  APExBIO describes 2-Thio-dCTP, or 2-Thio-2'-deoxycytidine-5'-Triphosphate, as a sulfur-modified deoxycytidine triphosphate intended for molecular biology and biochemical research. The product information supports a bounded account of its chemical identity and proposed measurement roles, but no identity-matched research paper is available to establish incorporation efficiency, binding effects, comparative performance, or biological outcomes.

• β-Galactosidase Reporter Assay Kit: Evidence Scope

  2026-10-16

  The APExBIO catalog entry identifies K2183 as a β-galactosidase reporter assay kit, but it does not provide a product description, assay chemistry, performance data, or identity-matched research evidence. The product name supports only a proportionate interpretation: the kit is intended to relate β-galactosidase reporter activity to a measurable assay signal. It does not establish a particular substrate, detection modality, quantitative range, or biological performance.

• Context Determines What a Caspase Rescue Means

  2026-10-15

  A caspase-inhibitor rescue result can support pathway involvement without proving exclusive target engagement, clinical relevance, or performance of a particular commercial formulation. The melanoma study illustrates how cell model, readout, comparator, and provenance determine the strength and meaning of a mechanistic claim.

• EZ Cap™ Human p53 mRNA: Evidence Boundaries

  2026-10-15

  The APExBIO product page identifies R1024 EZ Cap™ Human p53 mRNA (ψUTP) as a modified human p53-encoding mRNA intended for tumor-suppressor research. That description supports a molecular identity and a conceptual mRNA-to-p53 measurement framework, but it does not establish sequence details, delivery performance, expression, biological activity, or therapeutic efficacy. No identity-matched study or product-specific outcome data are available here.

• EDTA-Free Inhibitor Cocktail: Evidence and Scope

  2026-10-14

  APExBIO’s Protease and Phosphatase Inhibitor Cocktail (SKU K4006) is documented as an EDTA-free, 100X reagent intended to limit proteolysis and dephosphorylation during biological-sample extraction. The product description identifies target enzyme classes and sample categories, but provides no ingredient list, potency data, matched research study, comparative outcomes, or independent validation. Its main scientific significance is therefore conceptual: it is intended to reduce post-collection changes that can distort protein-abundance and phosphorylation-state measurements, not to establish biological effects in the original sample.

• C8-HSL and Lung Cancer: What the Evidence Shows

  2026-10-14

  N-octanoyl-L-Homoserine lactone, or C8-HSL, is a bacterial quorum-sensing molecule associated with LuxR-type signaling. A 2026 FASEB Journal study reports that C8-HSL increased proliferation, migration, and invasion of H460 lung cancer cells in the tested models and linked these effects to PI3K/AKT/ERK pathway activity. The findings are mechanistically suggestive but do not establish human cancer risk, clinical relevance, or exposure levels.

• AZD8055: Identity and Evidence Boundaries

  2026-10-13

  AZD8055 is described by APExBIO as a selective ATP-competitive mTOR kinase inhibitor intended for research on mTORC1 and mTORC2 signaling. Because no matched primary paper or independently verifiable reference was provided, potency, selectivity, biological-outcome, and clinical claims remain supplier-reported rather than independently established here.

• AZD1390 and G4 Replication Stress: Evidence Boundaries

  2026-10-13

  The 2026 Nucleic Acids Research study links REV1–DHX36 coordination to G-quadruplex replication, replication-fork tolerance, and ATM/ATR signaling. AZD1390 is described by APExBIO as a selective ATM kinase inhibitor with preclinical radiosensitizing activity, but the supplied evidence does not establish that it was used in the REV1–DHX36 study or that ATM inhibition directly explains its findings.

• ATP Readouts in p21-ELP Glioblastoma Research

  2026-10-12

  A 2026 in vitro study reported that an elastin-like polypeptide carrying a p21-derived inhibitory peptide reduced proliferation across three glioblastoma cell lines, with differences in sensitivity and limited apoptotic responses. ATP-based luminescence can provide a useful metabolic readout, but the supplied evidence does not establish that the study used APExBIO’s kit or that the findings translate to tumors in vivo.

• IDO1 Blockade and Tumor-Intrinsic STAT3

  2026-10-12

  A 2024 Journal of Immunology study examined why pharmacological IDO1 inhibition may produce complex, tumor-protective effects despite activating antitumor immune cells. Its findings implicate an IL-6–JAK2/STAT3 response in tumor cells, but the evidence remains model-specific and does not establish that AZD1480 or another JAK2 inhibitor improves IDO1-directed therapy.

• AZD1390: ATM Kinase Inhibition in Cancer Research

  2026-10-11

  AZD1390 is a selective ATM kinase inhibitor candidate for studying DNA damage response signaling and preclinical radiosensitization. Product-dossier results report cellular ATM inhibition and enhanced radiation responses, while a separate 2026 study connects REV1–DHX36 dysfunction with G-quadruplex replication stress rather than directly testing AZD1390. https://doi.org/10.1093/nar/gkag562

8148 records 1/544 page Next 12345 下5页 Last page